Search research articles
Contact Us
Filters
Showing results (191-200 of 344) with videos related to
Page
of 35
Sort By:
Investigational New Drugs
|
December 22, 2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Kohei Shitara, Satoshi Yuki, Motoki Yoshida, et al.
The Lancet. Oncology
|
May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara, Hiroji Iwata, Shunji Takahashi, et al.
ESMO Open
|
July 29, 2020
Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
Akinori Sasaki, Akihito Kawazoe, Testuya Eto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2020
The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
Yohei Kubota, Akihito Kawazoe, Akinori Sasaki, et al.
Frontiers in Oncology
|
November 17, 2022
A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
Aya El Helali, Jun Tao, Charlene H L Wong, et al.
Cancer Immunology Research
|
April 27, 2026
Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation
Nina Yi-Tzu Lin, Hirotomo Machiyama, Akihito Kawazoe, et al.
Oncology
|
November 8, 2011
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery
Kohei Shitara, Keitaro Matsuo, Chihiro Kondo, et al.
Investigational New Drugs
|
January 15, 2010
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
Kohei Shitara, Tomoya Yokota, Daisuke Takahari, et al.
The Clinical Journal of Pain
|
January 19, 2013
Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain
Motoo Nomura, Koichi Inoue, Shoko Matsushita, et al.
Therapeutic Advances in Medical Oncology
|
August 1, 2020
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, et al.
Page
of 35
Search research articles
Search
Showing results (191-200 of 344) with videos related to
Sort By:
Page
of 35
Investigational New Drugs
|
December 22, 2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Kohei Shitara, Satoshi Yuki, Motoki Yoshida, et al.
The Lancet. Oncology
|
May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara, Hiroji Iwata, Shunji Takahashi, et al.
ESMO Open
|
July 29, 2020
Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
Akinori Sasaki, Akihito Kawazoe, Testuya Eto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2020
The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
Yohei Kubota, Akihito Kawazoe, Akinori Sasaki, et al.
Frontiers in Oncology
|
November 17, 2022
A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
Aya El Helali, Jun Tao, Charlene H L Wong, et al.
Cancer Immunology Research
|
April 27, 2026
Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation
Nina Yi-Tzu Lin, Hirotomo Machiyama, Akihito Kawazoe, et al.
Oncology
|
November 8, 2011
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery
Kohei Shitara, Keitaro Matsuo, Chihiro Kondo, et al.
Investigational New Drugs
|
January 15, 2010
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
Kohei Shitara, Tomoya Yokota, Daisuke Takahari, et al.
The Clinical Journal of Pain
|
January 19, 2013
Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain
Motoo Nomura, Koichi Inoue, Shoko Matsushita, et al.
Therapeutic Advances in Medical Oncology
|
August 1, 2020
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, et al.
Page
of 35